Home Contact Center Add this

Let's meet

BioFit 2015

BioFit 2015
December 01-02, 2015ALL EVENTS

24 November 2015 / international

Debiopharm International SA’s partner Yakult Honsha Co, Ltd. announces Elplat® approbation in gastric cancer in Japan [Read more]

03 November 2015 / international

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston [Read more]

09 October 2015 / international

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award [Read more]


08 September 2015

Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy. [Read more]

16 April 2015

Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference [Read more]

18 November 2014

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona [Read more]


18 December 2014

Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities [Read more]

27 November 2014

Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD) [Read more]

17 November 2014

Coorpacademy, établi à l’EPFL et l’un des leaders des MOOCs à destination des entreprises, lève 3,2 millions d’euros auprès de Debiopharm Investment et du fonds français NextStage [Read more]


08 November 2015

Clinical Safety, Pharmacokinetics and Early Evidence of Activity of The Oral IAPs Inhibitor Debio 1143 in Combination with Carboplatin and Paclitaxel: a Phase1 Study [Read more]

23 October 2015

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells [Read more]

19 September 2015

Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and its Active Moiety Debio 1452, Administered Orally in Healthy Subjects [Read more]


bulle slideshow group

bulle slideshow diagnostics

bulle slideshow international

bulle slideshow investment

bulle slideshow research